DAEJEON, South Korea and CASTRES, France, Nov. 23, 2020 /CNW/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have announced their plans to form a ...

In oncology, Pierre Fabre Laboratories and the Californian biotech Atara Biotherapeutics have been working in partnership since 2021 to treat relapsed or refractory Epstein-Barr virus positive ...

CASTRES, France and CAMBRIDGE, England, Sept. 25, 2023 /PRNewswire/ -- Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to ...

Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. This first acquisition of a ...

About Pierre Fabre Pierre Fabre is a French healthcare company with over 35-years of experience in innovation, development, manufacturing and commercialization in oncology.

Overall, then, Pierre Fabre’s approach to lung cancer is rooted in precision medicine. “We are addressing EGFR exon20, EGFR exon19 resistance mechanisms, and MET amplification and exon 14 ...

Pierre Fabre Laboratories have received marketing authorisation in China for BRAFTOVI (encorafenib) in combination with cetuximab to treat adult patients with BRAFV600E-mutant metastatic colorectal ...

Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. This first acquisition of a ...